Form Approved
OMB No. 0920-1428
Expiration Date: 01/31/2027
mChoice: Improving PrEP Uptake and Adherence among Minority MSM through Provider Training and Adherence Assistance in Two High Priority Settings
Attachment 4i
Provider Pre-Training Assessment
Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-New)
TABLE OF CONTENTS
INTRODUCTION TEXT DEMOGRAPHICS
PrEP FAMILIARITY & ATTITUDES
PrEP USE & INTENTIONS
CULTURAL COMPETENCY & PrEP CARE
CONCLUSION TEXT
Thank you for your participation in this important project. This survey will take approximately 20 minutes to complete.
In this survey, we will ask some questions about your demographics and your knowledge and comfort around prescribing and talking with patients about HIV pre-exposure prophylaxis (PrEP). This survey includes questions around sensitive topics. Before beginning, please consider your surroundings and the privacy of your device and internet connection.
All the information you enter in this survey is encrypted and kept completely confidential. Your answers are private--the information you provide us will be kept secure and known only to study staff. You may choose "Decline to answer" on any questions that make you feel uncomfortable, or you are unsure of the answer.
We want to acknowledge that some of the language used in our study questions may include some outdated language or lack the diversity of experiences that we now understand exist. Although we do our best to use measures that reflect emerging language, at times the items available in research are not where they need to be and are drawn from items developed ten (or more) years ago. Wherever possible, we have updated the language or are working with developers to get new versions. Please remember that you can always decline to answer items that do not reflect you.
If you have any questions or comments, please contact study staff at son_mChoice@cumc.columbia.edu or (212)305-8198.
Please click the button below to get started with the survey.
Decline to answer
Yes
No
Decline to answer
African American or Black
American Indian or Alaskan Native
Asian
Native Hawaiian or other Pacific Islander
White
Decline to answer
Lesbian or gay
Straight, that is not lesbian or gay
Bisexual
Something else ____________
Decline to answer
Clinician (MD, DO, PA, NP, etc.)
Nurse
Medical assistant
Social worker or case manager
Adherence counselor
Peer advocate
Other, please specify:
Decline to answer
Decline to answer
Yes
No
Decline to answer
Yes
No
Decline to answer
[If above = Yes]
Decline to answer
Yes, please describe the training(s):
No
Decline to answer
How would you describe your level of familiarity with each of the following:
|
Very unfamiliar |
Somewhat familiar |
Neither familiar nor unfamiliar |
Somewhat familiar |
Very familiar |
Decline to Answer |
PrEP, generally |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Daily oral PrEP with Truvada®, emtricitabine/tenofovir disoproxil fumarate, or Descovy®, emtricibine/tenofovir alafenamide |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
On-demand PrEP with Truvada® emtricitabine/tenofovir disoproxil fumarate (also known as episodic or 2-1-1) |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Cabotegravir (CAB)-LA PrEP (injectable) |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
How confident do you feel discussing each of the following with patients?
|
Not at all confident |
Somewhat unconfident |
Neither confident nor unconfident |
Somewhat confident |
Very confident |
Decline to Answer |
PrEP generally |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Daily oral PrEP with Truvada®, emtricitabine/tenofovir disoproxil fumarate, or Descovy®, emtricibine/tenofovir alafenamide |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
On-demand PrEP with Truvada® emtricitabine/tenofovir disoproxil fumarate (also known as episodic or 2-1-1) |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
CAB-LA PrEP (injectable) |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Please respond to the following statements by indicating how much you agree or disagree.
|
Strongly agree |
Somewhat agree |
Neutral |
Somewhat disagree |
Strongly disagree |
Decline to Answer |
Prescribing PrEP will encourage patients to engage in risky sexual behavior. |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Patients prescribed PrEP are not likely to adhere to the medication. |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
People should use condoms instead of PrEP. |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Prescribing PrEP will lead to increased resistance to antiretroviral therapy (ART). |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Prescribing PrEP will lead to an increase in sexually transmitted infections (STIs). |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Please respond to the following statements by indicating how much you agree or disagree.
|
Strongly agree |
Somewhat agree |
Neutral |
Somewhat disagree |
Strongly disagree |
Decline to Answer |
Anyone who wants PrEP & doesn’t have any contraindications should be able to get it |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Patients will be more likely to adhere to injectable PrEP than daily oral PrEP |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
It will be harder to clinically manage patients who use injectable PrEP compared to oral PrEP |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Having more options for PrEP is beneficial to patients |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
[For clinicians only]
Yes
No
Decline to answer
[for clinicians only if yes to ? above]
|
Completely uncomfortable |
Somewhat uncomfortable |
Neither comfortable nor uncomfortable |
Somewhat comfortable |
Completely comfortable |
Decline to Answer |
N/A |
Patients in your clinic, generally |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Patients under age 18 years |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Patients who identify as gay, bisexual, or men who have sex with men |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Patients who identify as transgender male or female |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Patients who identify as heterosexual |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
[If above = Yes]
Daily oral: Truvada®, emtricitabine/tenofovir disoproxil fumarate, or Descovy®, emtricibine/tenofovir alafenamide
On-demand oral (2-1-1, episodic): Truvada®, emtricitabine/tenofovir disoproxil fumarate
CAB-LA (injectable)
Other, specify:
Decline to answer
[For clinicians only]
|
Approximate number of patients in your care on each type of PrEP |
Approximate number of PrEP prescriptions you’ve written in the past year (new + refills) |
Decline to answer |
Daily oral PrEP with Truvada®, emtricitabine/tenofovir disoproxil fumarate, or Descovy®, emtricibine/tenofovir alafenamide |
|
|
|
On-demand PrEP with Truvada® emtricitabine/tenofovir disoproxil fumarate (also known as episodic or 2-1-1) |
|
|
|
CAB-LA (injectable) |
|
|
|
Other PrEP regimen: Specify |
|
|
|
[if prescribed daily oral or on-demand in past year]
Almost all Truvada® and no Descovy®
More Truvada® than Descovy®
About the same amount of Truvada® and Descovy®
More Descovy® than Truvada®
Almost all Descovy® and no Truvada®
Decline to answer
[if prescribed more or almost all Descovy®, emtricibine/tenofovir alafenamide compared to Truvada®, emtricitabine/tenofovir disoproxil fumarate]
I feel more knowledgeable on Descovy® compared to Truvada®
I think Descovy® has fewer side effects compared to Truvada
Patients prefer Descovy® compared to Truvada
Other, specify:
Decline to answer
[For clinicians only]
I don’t feel knowledgeable about on-demand PrEP compared to other PrEP modalities
I don’t believe that this specific PrEP modality should be used
I am lacking the necessary clinic support/infrastructure
I don’t think patients will be able to afford it
I don’t know what barriers
Other, please specify:
Decline to answer
[If don’t believe modality should be used is selected above]
Patients will be less adherent compared to other modalities
Patients won’t be able to predict when they will have sex
The on-demand dosing schedule is not FDA approved
On-demand PrEP is less effective than other modalities
On-demand PrEP is less safe than other modalities
On-demand PrEP will encourage riskier sexual behavior compared to other modalities
It will be harder to clinically manage patients using on-demand PrEP compared to other modalities
Other, please specify:
Decline to answer
[For clinicians only]
I don’t feel knowledgeable about injectable PrEP compared to other PrEP modalities
I don’t believe that this specific PrEP modality should be used
I am lacking the necessary clinic support/infrastructure
I don’t think patients will be able to afford it
I don’t know what barriers
Other, please specify:
Decline to answer
[If don’t believe modality should be used is selected above]
Patients will not be able to keep/travel to injection appointments
Patients will not tolerate the side effects compared to other modalities
Injectable PrEP is less effective than other modalities
Injectable PrEP is less safe than other modalities
It will be harder to clinically manage patients using injectable PrEP compared to other modalities
Injectable PrEP will encourage riskier sexual behavior
Other, please specify:
Decline to answer
[For clinicians only]
|
Very unlikely |
Somewhat unlikely |
Neutral |
Somewhat likely |
Very likely |
Decline to Answer |
Pre-exposure prophylaxis (PrEP), generally |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Daily oral PrEP with Truvada®, emtricitabine/tenofovir disoproxil fumarate, or Descovy®, emtricibine/tenofovir alafenamide |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
On-demand PrEP with Truvada® emtricitabine/tenofovir disoproxil fumarate (also known as episodic or 2-1-1) |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
CAB-LA PrEP (injectable) |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
[For clinicians only]
More PrEP prescriptions than last year
About the same amount of PrEP prescriptions
Fewer PrEP prescriptions than last year
Decline to answer
Very unfamiliar
Somewhat familiar
Neither familiar or unfamiliar
Somewhat familiar
Very familiar
Decline to answer
Yes, please describe the training(s):
No
Decline to answer
|
Always |
Usually |
Often |
Sometimes |
Never |
Decline to Answer |
Identify and challenge your own cultural assumptions, values, and beliefs |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Avoid using your cultural norms as the standard to assess people from other identities or backgrounds |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Develop positive attitudes towards cultural differences |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Use an inclusive approach that is not judgmental or potentially stigmatizing |
☐ |
☐ |
☐ |
☐ |
☐ |
Completely uncomfortable
Somewhat uncomfortable
Neither comfortable nor uncomfortable
Somewhat comfortable
Completely comfortable
Decline to answer
Very unfamiliar
Somewhat familiar
Neither familiar or unfamiliar
Somewhat familiar
Very familiar
Decline to answer
Yes
No
[If 35 is Yes]
|
Always |
Usually |
Often |
Sometimes |
Never |
Decline to Answer |
Allow the patient to guide the conversation |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Use open-ended questions to inquire about sexual behaviors and ask follow-up questions for clarity |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Use a non-judgmental approach |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Use layman’s terms alongside anatomically accurate terms |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Use positive reinforcement for behaviors you want to encourage |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Validate and normalize the experiences of your patients |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Repeat/rephrase the patient’s responses to demonstrate active listening |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
|
Always |
Usually |
Often |
Sometimes |
Never |
Decline to Answer |
Questions regarding reason for the patient’s visit |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Questions regarding the patient’s history of HIV testing |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Questions regarding the patient’s knowledge about HIV |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Questions regarding the patient’s sexual practices |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Questions regarding the patient’s use of preventative methods against HIV and other STIs |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Questions regarding the patient’s past history of STIs |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Questions regarding the patient’s use of drugs and alcohol |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
Questions regarding the patient’s knowledge of PrEP/PEP |
☐ |
☐ |
☐ |
☐ |
☐ |
☐ |
[If 35 is No]
I do not feel comfortable
My patients do not feel comfortable
It is not relevant to my practice
It is not important
Other, please specify: _______
Decline to answer
Thank you for completing this survey for the mChoice study. Your responses are very important to us and we appreciate your time.
File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
Author | Mitchell, Jessica |
File Modified | 0000-00-00 |
File Created | 2024-08-09 |